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Abstract
Neuromyelitis optica/spectrum disorder (NMO/SD) is a severe, inflammatory disease of the central nervous system
(CNS). In the majority of patients, it is associated with the presence of pathogenic serum autoantibodies (the
so-called NMO-IgGs) directed against the water channel aquaporin 4 (AQP4), and with the formation of large,
astrocyte-destructive lesions in spinal cord and optic nerves. A large number of recent studies using optical
coherence tomography (OCT) demonstrated that damage to optic nerves in NMO/SD is also associated with
retinal injury, as evidenced by retinal nerve fiber layer (RNFL) thinning and microcystic inner nuclear layer
abnormalities. These studies concluded that retinal injury in NMO/SD patients results from secondary
neurodegeneration triggered by optic neuritis.
However, the eye also contains cells expressing AQP4, i.e., Müller cells and astrocytes in the retina, epithelial
cells of the ciliary body, and epithelial cells of the iris, which raised the question whether the eye can also
be a primary target in NMO/SD. Here, we addressed this point in experimental NMO/SD (ENMO) induced in
Lewis rat by transfer of AQP4268–285-specific T cells and NMO-IgG.
We show that these animals show retinitis and subsequent dysfunction/damage of retinal axons and neurons,
and that this pathology occurs independently of the action of NMO-IgG. We further show that in the retinae
of ENMO animals Müller cell side branches lose AQP4 reactivity, while retinal astrocytes and Müller cell
processes in the RNFL/ganglionic cell layers are spared. These changes only occur in the presence of both
AQP4268–285-specific T cells and NMO-IgG.
Cumulatively, our data show that damage to retinal cells can be a primary event in NMO/SD.
Introduction
Optic nerves and spinal cord are preferential targets of
inflammation in NMO/SD, an astrocytopathic disease of
the central nervous system (CNS) associated with the
presence of pathogenic serum autoantibodies directed
against AQP4 [1–3]. A large number of recent studies
using optical coherence tomography (OCT) demon-
strated that damage to optic nerves in NMO/SD is also
associated with retinal injury [4]. This finding raised the
questions whether retinal injury in NMO/SD patients
only results from secondary neurodegeneration triggered
by optic neuritis, whether it may also be a consequence
of retinal inflammation initiated by AQP4-specific T
cells, and whether there is a contribution of pathogenic
AQP4-specific antibodies to this process. These ques-
tions were especially important since AQP4, the target
antigen for both, is expressed in the eye: by Müller cells
and astrocytes in the retina [5], and by epithelial cells of
the ciliary body and the iris [6]. To address these points,
we searched for ocular inflammation in experimental
NMO/SD (ENMO).
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All animal experiments were approved by the Ethic Com-
mission of the Medical University Vienna and performed
with the license of the Austrian Ministery for Science and
Research (GZ66.009/195-WF-V-3b/2015;GZ66.009/0241-
WF/II/3b/2014). Lewis rats were obtained from Charles
River Wiga (Sulzfeld, Germany), and were used at an age
of 7–8 weeks. During the experiments, they were housed
in the Decentral Facilities of the Institute for Biomedical
Research (Medical University Vienna) under standardized
conditions.
T cells and immunoglobulins used in transfer experiments
The T cells used were specific for rat AQP4268–285
(KAAQQTKGSYMEVEDNRS) which contains two over-
lapping epitopes for antigen presentation via RT1.BL:
QQTKGSYME, and TKGSYMEVE, and were grown
under culture conditions selecting the T-helper 1 subset
of CD4+ T cells [7–9].
The plasmapheresates used as sources for NMO-IgG
were termed NMO-IgG9, NMO-IgGV, and NMO-IgGS.
NMO-IgG9 derived from a Japanese NMO/SD patient
with optic neuritis only, NMO-IgGV from an Austrian
NMO/SD patient with optic neuritis followed 5 months
later by myelitis, and NMO-IgGS from a Swedish NMO/
SD patient with repeated optic neuritis and myelitis, and
with additional MS-typical brain lesions. NMO-IgG9 and
NMO-IgGV were purified using Protein G Sepharose 4
Fast Flow (GE Healthcare Bio-Sciences, Pasching,
Austria) according to the manufacturer’s instructions,
and adjusted to a concentration of 10 mg/ml. NMO-
IgGS was injected as plasmapheresate without further
purification. The use of the plasmapherisates/NMO-IgG
preparations for research was approved by the Ethics
Committee of Tohoku University School of Medicine
(No. 2007–327), by the Regional and National Ethical
Committee of Sweden (2013/153-31 Linköping), and by
the Ethics Committees of the Medical University of
Vienna (No. 1005/2014).
As negative control (co-IgG), commercially available
normal human IgG (Subcuvia™, Baxter, Vienna) was
used, diluted with phosphate buffered saline (PBS) to an
IgG concentration of 10 mg/ml prior to use.
Induction of ENMO and tissue preparation
ENMO was induced by intraperitoneal injection of
1x107 AQP4268–285-specific T cells on day 0, followed
by intraperitoneal injection of NMO-IgG on day 4 or
5. A few animals received 3x106 AQP4268–285-specific
T cells on day 0, followed by intraperitoneal injection
of NMO-IgG on day 5. The animals were then killed
24–48 h later with CO2 and perfused with 4 % para-
formaldehyde in phosphate-buffered saline. The eyes
were dissected, immersed for another 18–24 h in
PFA and embedded in paraffin for histological
analysis.
Histological and immunohistochemical analysis
All stainings were done essentially as described [10, 11]
using rabbit polyclonal antibodies against AQP4 (Sigma,
Germany), rabbit polyclonal against glial fibrillary acidic
protein (GFAP; from Dako, Denmark), rabbit polyclonal
antibodies against CD3 (to stain T cells; NeoMarkers,
Fremont, USA), rabbit polyclonal antibodies against ni-
tric oxide synthetase II (AB16311; Merck Millipore,
Darmstadt, Germany), the mouse monoclonal antibody
ED1 (to stain macrophages and activated microglia;
Serotec, Germany), the mouse monoclonal anti-glutamine
synthetase antibody (BD Biosciences, San Jose, USA), anti-
human immunoglobulin (biotinylated donkey; polyclonal;
Amersham, UK), anti-complement C9 (rabbit polyclonal
[12]), and mouse monoclonal antibodies against
amyloid-beta precursor protein (APP; Merck Millipore,
Massachusetts, USA).
Counting and statistics
Counting was performed manually at 100 ×, 200 × or
400 × magnification using a morphometric grid. One
slide contained two sagittal sections of one eye and
one coronal section of the contralateral eye of the
same animal. For quantification of the number of T
cells in the retina, ciliary body, and iris, the largest
inflammatory lesion per slide was chosen for each
animal studied, and counted at 100 ×magnification.
For quantification of the number of T cells in differ-
ent layers of the retina, one representative inflamma-
tory lesion per slide and animal was chosen and
counted at 100 ×magnification. For quantification of
the number of T cells proximal or distal to the optic
nerve T cells in the whole proximal or distal sagittal
sections were counted. To determine the number of
APP+ spheroids, the largest lesion with APP+ struc-
tures was counted in the retina, papilla, and in the
center and periphery of the optic nerve, using a
400 × magnification.
Statistics were calculated with IBM SPSS Statistics 21.
The Mann-Whitney (Wilcoxon) U test and student’s t-
test were used for statistical analysis. For multiple com-
parison corrections Bonferroni and Bonferroni-Holm
was used.
Results
The anterior visual pathway in ENMO
In ENMO, brain lesions with AQP4 loss occur on a
background of diffuse T cell infiltration, are found in
many different sites and may hit structures of the anter-
ior visual pathway, but do not specifically target them
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(Fig. 1). Also the optic nerves of ENMO rats contain
many T cells, but astrocyte-destructive lesions are essen-
tially absent (Fig. 1).
Intraocular T cells in ENMO
Transfer of AQP4268–285-specific T cells (with or without
NMO-IgG) into Lewis rats led to T cell infiltrates in ret-
ina and ciliary body. However, only the retinal T cell in-
filtration remained statistically significant, when these
rats were compared to their counterparts injected with
antibodies only (Fig. 2). In the iris, there was no increase
in T cell numbers after injection of AQP4268–285-specific
T cells and NMO-IgG. In fact, T cell numbers were even
statistically higher in animals injected with NMO-IgG
only, and in NMO-IgG injected rats compared to the co
IgG/PBS group. However, since the overall numbers of
T cells at this site were very low, we did not further fol-
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Fig. 1 Inflammation and astrocyte-destructive lesions in the anterior visual pathway. Shown here is a scheme of the anterior visual pathway in rats
(a) and schemes of cross sections through the brain at different levels along the neuraxis to show important areas of the anterior visual pathway
(b,g,l,p) which were then analyzed in ENMO rats following staining with anti-CD3 antibodies (brown) to visualize T cell infiltrates (c,h,m,q), and
with anti-AQP4 antibodies (brown) to visualize loss of AQP4 reactivity (d,i,n,r). *: lesions with AQP4 loss outside the anterior visual pathway. Black
boxes: selected regions shown after staining with anti-GFAP antibodies (brown, e,f,j,k,o,s). Hematoxylin staining was used to reveal nuclei (blue).
For all drawings, schemes provided by Paxinos and Watson [38] and by Mueller [39] served as guide lines. Bars = 500 μm (c,d,h,i,m,n), 300 μm
(q,r,s), and 100 μm (e,f,j,k,o)
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Instead, we next only studied the retina in more detail.
Since in these initial ocular studies, 3x106 AQP4268–285-
specific T cells have been injected, which was not suffi-
cient to induce retinitis in all experimental animals
(Fig. 2), we used for all following experiments 1x107
AQP4268–285-specific T cells and NMO-IgG to induce
ENMO, to have a more stable model for studying the
consequences of T cell infiltration into the retina. We
found, that retinal T cell distribution followed two differ-
ent gradients. The first gradient was proximal - > distal
of the papilla, with most retinal T cells and perivascular
T cell clusters found in close vicinity to or within the
optic nerve head (Fig. 3). The second gradient was an in-
side - > outside gradient of infiltration, in which the
highest numbers of intraparenchymal and perivascular
retinal T cells was seen in the nerve fiber/ganglion cell/
inner plexiform layers, lower numbers in the outer plexi-
form and nuclear layers, and essentially no T cells in the
layers of rods and cones (Fig. 3). Sometimes, this gradi-
ent was interrupted by rare areas of perivascular T cell
infiltration at vessels crossing through several retinal
layers, mostly involving the outer nuclear/inner plexi-
form/inner nuclear layers (Fig. 3). Rarely, we also saw T
cells in retinal pigment epithelium and choroid, but did
not follow this up further (data not shown).
In ENMO, AQP4-specific T cells cause axonal pathology
predominantly in the retinal nerve fiber/ganglionic cell
layer
In NMO/SD patients, thinning of the retinal nerve fiber
and ganglion cell layers is considered a secondary conse-
quence of optic neuritis [4]. However, in EAE models,
encephalitogenic T cells are able to directly cause transi-
ent and permanent injury of neurons, as revealed by the
formation of axonal spheroids and end bulbs [13]. Is
there evidence for axonal injury in the retina of our
ENMO animals? To address this question, we next
searched for APP+ spheroids/end bulbs and iNOS+ mye-
loid cells at this site. We found inflammatory lesions
with APP+ axonal spheroids/end bulbs in the retinal
nerve fiber/ganglionic cell layer, and significantly more
APP+ structures in retina and papilla than in the extra-
ocular optic nerve. These pathological changes could be
clearly ascribed to the action of AQP4268–285-specific T
cells, since T cells triggered the formation of APP+ struc-
tures both in the presence and in the absence of NMO-
IgG (Fig. 4). Retinal APP+ axonal spheroids/end bulbs
co-localized with iNOS+ macrophages/microglia (Fig. 4).
In ENMO, RNFL astrocytes are spared and Müller cells are
damaged
The healthy retina is protected from serum antibodies
by the inner and outer blood–retinal barriers (BRB) (30),
but these barriers can be opened by inflammatory T
cells, allowing the entry of NMO-IgG. Could this cause
antibody-mediated damage to AQP4-expressing retinal
astrocytes or Müller cells?
Fig. 2 Retinitis in the eye of animals with ENMO. Median T cell numbers
seen in the largest lesion within the retina (a), ciliary body (b) and iris
(c) per rat after injection of AQP4268–285-specific T cells and NMO-IgG
(n= 10), AQP4268–285-specific T cells and control IgG (n= 12), NMO-IgG
(n= 10), and control IgG (n= 3) or PBS (n= 2). The animals receiving
control IgG and PBS were pooled (P). (a) In the retina, differences be-
tween NMO-IgG injected and control IgG or PBS injected rats were not
significant (p= 0.505), while differences between this group and the
AQP4268–285-specific T cells and NMO-IgG injected and the AQP4268–285-
specific T cells and control IgG injected groups were significant (* p=
0.03 and 0.044, respectively). (b) In the ciliary body, there were no
statistically significant differences between the 4 different groups after
correction for multiple comparison. (c) In the iris, statistically higher
numbers of T cells were found in animals injected with NMO-IgG only
in comparison to the AQP4268–285-specific T cells and NMO-IgG and
the co IgG/PBS injected groups (* p = 0.038 and 0.031, respectively,). In
all cases, the Mann-Whitney exact U test with Bonferroni correction for
multiple comparisons was used
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To address this question, we first concentrated on the
retinal nerve fiber/ganglionic cell layer containing most
retinal astrocytes [14] and the terminal processes of
Müller cells [15]. We did not see any evidence for AQP4
loss or for the formation of astrocyte-destructive lesions
in these layers (Table 1): There was only little leakage of
serum proteins like rat and human IgG and complement
at the retinal nerve fiber/ganglionic cell layer, and we did
not see the accentuated surface staining of astrocytic or
Müller cell processes indicative of IgG or complement
deposition on these cells (Fig. 5).
Next, we concentrated on inflammatory lesions in the
inner plexiform/inner nuclear/outer plexiform/outer nu-
clear layers, where leakage of complement proteins and of
rat and human IgG was more severe than the leakage seen
in the retinal nerve fiber/ganglionic cell layer (Fig. 5), and
where NMO-IgG should primarily target Müller cells,
which have their perikarya in the inner nuclear layer, their
stem processes spanning throughout the entire thickness
of the retina, and their side branches in the outer and
inner plexiform layers [14, 15] (Fig. 5). We found lesions
with AQP4 loss in the outer plexiform layer (Table 1). To
make sure that the AQP4 loss in the INL/OPL/ONL area
was not a pathological feature unique to one NMO-IgG
only, we also tested NMO-IgG from different sources
(NMO-IgGs, NMO-IgGV, or NMO-IgG9). We observed
AQP4 loss with NMO-IgG preparations from different pa-
tients (Table 1). The loss of AQP4 reactivity in the OPL
was not caused by a cellular displacement due to inflam-
matory infiltrates, since there was no accumulation of glu-
tamine synthetase or of GFAP expressing cells/cellular
processes in the perilesional area (Figs. 5 and 6). We also
Fig. 3 Two gradients of T cell infiltration into the retina. a CD3+ T cells (brown) in papilla and peripapillary retina. b statistically significant
differences in T cell numbers proximal and distal from the papilla, as determined from 1 whole retinal section each of 9 and 13 rats, respectively
(p = 0.000076 according to Mann-Whitney U test; plots show the range of T cell numbers (whiskers) with 50 % scores (interquartile range, boxes)
centered around median values (horizontal lines within boxes), and mild outliers (circles). c Retinal cross section show an inside - > outside gradient of
CD3+ T cells (brown). RNFL: retinal nerve fiber layer, GCL: ganglionic cell layer, IPL: inner plexiform layer, INL: inner nuclear layer, OPL: outer plexiform
layer, ONL: outer nuclear layer, R + C: layer of rods and cones. d Quantification of T cell infiltration in different retinal layers, as determined from one
representative lesion/rat (n = 5 rats; **p = 0.003, t-test, Bonferroni-correction for multiple comparisons). e Invasion of CD3+ T cells (brown) from vessels
spanning the different retinal layers. The contribution of retinal and choroid vasculature to the blood supply is indicated. Bars = 525 μm (a) and
100 μm (c,e). All histological sections were counterstained with hematoxylin to show nuclei in blue; (*) perivascular T cell clusters



























































Fig. 4 Axonal spheroids/end bulbs in retina, papilla, and optic nerve. Sections through the optic nerve head (a, b), ganglionic cell layer (c-e,
consecutive sections) and retinal nerve fiber layer (f) were reacted with antibodies against APP (a-c, f), iNOS (d), and AQP4 (e). Antibody binding
is shown in brown, and the nuclei are revealed by counterstaining with hematoxylin. The tissue sections derived from Lewis rats injected with
AQP4268–285-specific T cells and either NMO-IgG (a,c-f) or co-IgG (b). APP
+ axonal spheroids/endbulbs can be seen upon the induction of
inflammation by AQP4268–285-specific T cells in presence and absence of NMO-IgG (a-c, f), and coincide with iNOS
+ macrophages (d) and
essentially normal AQP4 expression (e). Bars = 25 μm. g Numbers of APP+ spheroids/endbulbs in the most affected lesion per rat, found
in retina (RET), papilla (PAP), and central or peripheral parts of optic nerve cross sections (cON or pON, respectively), as determined from
11 rats injected with T cells and NMO-IgGs, and from 8 rats injected with NMO-IgGs only. The numbers of APP+ spheroids/end bulbs
were significantly higher in retina and papilla compared to central and peripheral optic nerve (p = 0,002, Mann-Whitney U-test). h Numbers of APP+
spheroids/endbulbs in the most affected retinal and papillary lesion per rat, found in animals injected with AQP4268–285-specific T cells/
NMO-IgG (n = 15; NMO-IgG from 3 different sources), AQP4268–285-specific T cells/control IgG (coIgG) (n = 8) and NMO-IgG only (n = 12).
The differences between the T cell injected groups and the group receiving NMO-IgG only were significant (**p = 0.006 and *p = 0.025,
respectively; Mann-Whitney U-test with Bonferroni-Holm correction)
Table 1 The numbers of perivascular cuffs (total numbers/numbers with AQP4 loss) in retinal nerve fiber layer (RNFL), inner nuclear
layer (INL), outer plexiform layer (OPL), and outer nuclear layer (ONL), as determined from one retinal section/rat
Treatment # rats # of perivascular cuffs in RNFL (total/AQP4 loss) # of perivascular cuffs in INL/OPL/ONL (total/with AQP4 loss)
T + NMO-IgGS 5 5/0 3/1
T + NMO-IgGV 4 8/0 12/8
T + NMO-IgG9 2 6/0 n.d.
T + co-IgG 4 17/0 8/0
Please note that not every inflammatory lesion in the INL/OPL/ONL region was associated with AQP4 loss. This was also observed in spinal cord sections of Lewis
rats with experimental NMO [9, 11]
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did not see any evidence for deposition of C9 or human
IgG on the surface of Müller cell bodies or stem processes
(Figs. 5 and 6). AQP4 loss was only seen in the presence
of both AQP4268–285-specific T cells and NMO-IgG.
Discussion
We show here that damage to retinal axons and neurons
in ENMO can be a primary event provoked by the
induction of inflammatory lesions. These pathological
changes could be clearly ascribed to the action of
AQP4268–285-specific T cells, since T cells triggered the
formation of APP+ structures both in the presence and
in the absence of NMO-IgG. We further show that in
ENMO, Müller cell side branches in the outer plexiform
layer lose AQP4 reactivity. This effect is only seen when
AQP4268–285-specific T cells induced inflammatory
lesions in the presence of NMO-IgG.
The induction of ocular inflammation is not a unique
feature of AQP4268–285-specific T cells, but also occurs
when sufficient numbers of activated T cells specific for
other ocular antigens are found in the circulation. Exam-
ples are T cells specific for the astrocytic S100β protein
[16], for myelin basic protein (MBP) [17–19] which is a
component of myelinated nerve bundles in the iris [20],
and for the retinal soluble antigen (S-Ag) [21] or the cel-
lular retinaldehyde binding protein (CRALBP) [22].
In the inflamed retina, AQP4268–285-specific T cells are
predominantly found both within the parenchyma and
within perivascular cuffs in the optic nerve head and in
the peripapillary retina, and display two gradients of cel-
lular distribution: the first one proximal - > distal of the
optic nerve head, and the second one from inner - >
outer retinal layers. The proximal - > distal gradient can
be explained by anatomical properties of the vasculature:
T cells enter at postcapillary venules, capillaries from the
surface of the papilla are in direct continuation with ca-
pillaries of the peripapillary retina [23], and the number
of capillary layers decreases from four in the peripapil-
lary inner retina to two and one in more centrifugally lo-
cated inner retinal parts [24]. The gradient from inner
- > outer retinal layers reveals that the majority of T cells
infiltrating the retina comes from the retinal vasculature
which forms the inner blood-retina barrier [25]. Inter-
spersed into these gradients is a small population of T
cells in close vicinity to blood vessels spanning through
the different retinal layers. At least some of these cells
might cross through the choroidal vasculature which
comprises the outer blood-retina barrier [25, 26].
Retinal T cell infiltration causes axonal pathology in the
RNFL and in the optic nerve head, as evidenced by the
presence of APP+ axonal spheroids/end bulbs. In the
RNFL, these structures were associated with iNOS+ acti-
vated microglia/macrophages, in line with a breakdown of
the inner blood-retinal barrier by pro-inflammatory









Fig. 5 Histological characterization of inflammatory lesions in the
retina. Consecutive retinal sections were reacted with antibodies
against CD3, ED1, rat IgG, AQP4, GFAP, glutamine synthetase (GS),
C9, and human IgG. Positive reaction products are shown in brown
or red (C9 only). All sections were counterstained with hematoxylin
to reveal nuclei in blue. Bars = 100 μm. The tissue derived from
animals injected with AQP4268–285-specific T cells and NMO-IgG
(ENMO), with AQP4268–285-specific T cells and human control IgG (T +
co IgG) and healthy controls, and show inflammation at the inner
blood retinal barrier (IBRB), at the outer blood retinal barrier (OBRB),
simultaneously at both retinal barriers (I/OBRB), or an absence of
inflammation at these sites in the control animals. The insert shown for
the GS stained retina of the rat injected with T cells and co IgG refers
to the area labeled by a white star in the adjacent overview. It
demonstrates that there is no loss of GS reactivity at this site,
but the lumen of a blood vessel. Bar = 100 μm
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cytokines [27] and reactive oxygen and nitrogen species
[28]. Possibly, the unmyelinated phenotype of retinal
axons renders them especially susceptible to the damaging
action of reactive nitric oxide species. The numbers of
lesions with axonal pathology per retinal section were too
small (on average 0.3/retinal section) to warrant transla-
tion of axonal dysfunction/loss into a measurable thinning
of the RNFL. In addition, the absence of a macula in rats
[29] also precludes a recapitulation of the macular thin-
ning observed in NMO/SD patients. In the papilla, APP+
axonal spheroids/end bulbs were not associated with
iNOS+ microglia/macrophages. This could suggest either
that axonal pathology was initiated more proximally to
the neuronal cell body, i.e., in the retinal nerve fiber layer/
ganglionic cell layer, or different ages of inflammatory
lesions in papilla and retinal nerve fiber/ganglionic cell
layer, since iNOS expression by microglia/macrophages is
temporally restricted [13]. We did not find APP+ axonal
spheroids/end bulbs in the outer plexiform/inner nuclear
layer, although there were lesions with iNOS+ cells at this
site. On the one hand, this could be due to immunomodu-
latory mediators acting at the outer blood-retinal barrier,
among them interleukin-10 and pigment epithelium-
derived factor, which could skew myeloid cells towards
higher phagocytic actions [25, 30]. On the other hand, the
axons of horizontal/bipolar cells found at this site might
be too short to form spheroids/end bulbs detectable by
our staining technique. Hence, axonal dysfunction/loss in
the RNFL is a primary outcome of ENMO, but not the
only one.
Müller cell side branches in the outer plexiform layer
lose AQP4 reactivity, while the terminal processes of
Müller cells and astrocytes in the RNFL remain intact.
The most likely explanation for this finding is the higher
amount of leakage of IgG and complement at the outer
blood-retina barrier than at the inner blood-retina barrier.
The AQP4 loss of Müller cell side branches was not a
consequence of complement-dependent (CDC) or of anti-
body dependent cellular cytotoxicity (ADCC), since there
was no evidence for complement or immunoglobulin
deposition on these cells. In this aspect, our observations
in ENMO animals reflect recent findings in 3 retinae from
NMO/SD autopsy cases, where Müller cells displayed a
unique dynamics with scattered loss of AQP4 reactivity,
and where the authors also concluded that the patho-
logical process in the retina may not involve CDC or
ADCC [31]. We do not know yet whether the scattered
loss of AQP4 reactivity on Müller cells is caused by
internalization of antibody-loaded AQP4, or whether it
reflects the response of these cells to inflammatory cyto-
kines or to injury of retinal neurons. The local loss of
AQP4 reactivity on Müller cell processes in the outer
plexiform layer could render these cells more susceptible
to osmotic stress without changing their expression levels
of GFAP, in line with previous findings in AQP4 null mice
[32, 33]. We also do not know yet how long the effects on
Müller cells last – especially since we saw loss of AQP4
reactivity under conditions of T cell infiltration and micro-
glia activation/macrophage recruitment, while the 3 hu-
man retinae described did not contain T cells or B cells
[31]. There is currently still some controversy about the
role of T cells in NMO/SD. However, since T cells are
found in early active lesions of NMO/SD patients [8, 34],
and since AQP4-specific T cells are found in the normal
immune repertoire of humans, and are expanded in the
repertoire of NMO/SD patients [35–37], their possible
contribution to retinal pathology in NMO/SD patients
should not be ignored. Further studies are needed to spe-
cifically address this point.
Cumulatively, however, our pathological findings in
the ENMO retina, and the recent study on NMO/SD
retinae [31] come both to the same conclusion: Damage
to the retina in NMO/SD may not only be caused by
secondary retrograde changes after optic neuritis, but
may also be a primary outcome of the disease.
Conclusions
We showed here that rats with ENMO developed retin-
itis, which was associated with two types of retinal dam-
age: With the formation of APP+ axonal spheroids/end
bulbs in retina and papilla which could be clearly as-
cribed to the action of AQP4268-285-specific T cells, and
Fig. 6 Histological characterization of AQP4 loss in the outer plexiform layer. Consecutive sections of an inflammatory retinal lesion of an animal
injected with AQP4268–285-specific T cells and NMO-IgG, reacted with antibodies against GFAP (a), AQP4 (b) and GS (c). Bar = 100 μm
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with the loss of AQP4 reactivity in Müller cell side
branches in the outer plexiform layer which was only
seen when AQP4268-285-specific T cells and NMO-IgG
were present. Currently, it remains unclear whether such
pathological changes also occur in the retina of NMO/
SD patients. To address this issue, peripapillary retinae
of these patients have to be studied at the peak of optic
neuritis.
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